Dtsch Med Wochenschr 2021; 146(05): 317-322
DOI: 10.1055/a-1235-0533
Dossier

Die Niere als Schrittmacher kardiovaskulärer Alterung

Kidney as pacemaker for cardiovascular aging
Christoph Wanner
,
Jan Galle
,
Kai Lopau

Nierenkranke altern schneller und vaskuläre Risikofaktoren verstärken den Prozess. SGLT2-Inhibitoren spielen eine signifikante Rolle im Erhalt der Organfunktion, und auch in den Leitlinien werden diese bei diabetischer Nierenerkrankung priorisiert. Auch die Therapie der Herzinsuffizienz wird diesbezüglich neu überdacht. Wie die Prävention interdisziplinär gelingen kann, zeigt der folgende Beitrag.

Abstract

Kidney patients age faster and vascular risk factors intensify the process. Lifetime is reduced up to 16 years in patients with diabetes mellitus type 2 and kidney disease. SGLT2 inhibitors play a significant role in maintaining organ function. By inhibiting the SGLT2 transporter in the proximal tubule of the kidneys, energy and water are continuously excreted and metabolic processes that are counter-regulated are set in motion. This hypometabolic adaptation supports organ functions and induces longevity. Kidney protection extends life expectancy of patients with diabetes mellitus type 2.

Also patients with heart failure benefit and a 3-stage therapy is newly being discussed. The beta blocker is combined with an SGLT2 inhibitor in the first stage. In the second stage, the angiotensin receptor/neprilysin inhibitor and then a mineralocorticoid receptor antagonist (MRA) is used. These therapies have a complementary effect.



Publication History

Article published online:
01 March 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • Literatur

  • 1 Wen CP, Chang CH, Tsai MI. et al Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int 2017; 92: 388-396
  • 2 Raschenberger J, Kollerits B, Titze S. et al Association of relative telomere lengths with cardiovascular disease in a large chronic kidney disease cohort: the GCKD study. Atherosclerosis 2015; 242: 529-534
  • 3 Fazzini F, Lamina C, Raftopoulou A. et al GCKD Investigators. J Intern Med 2021; DOI: 10.1111/joim.13242.
  • 4 Jager KJ, Kovesdy C, Langham R. et al A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Nephrol Dial Transplant 2019; 34: 1803-1805
  • 5 Hasslacher C. Similar risks of nephropathy in patients with type 1 or type 2 diabetes mellitus. Nephrol Dial Transplant 1989; 4: 859-863
  • 6 de Boer IH, Caramori ML, Chan JCN. et al Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. Kidney Int 2020; 98: 839-848
  • 7 Zlicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 2017; 12: 2032-2045
  • 8 Cosentino F, Grant PJ, Aboyans V. et al ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255-323
  • 9 Wanner C, Krane V, März W. et al Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248
  • 10 Schneider MP, Hübner S, Titze SI. et al Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates. Kidney Int 2015; 88: 1411-1418
  • 11 Anders HJ, Davis JM, Thurau K. Nephron protection in diabetic kidney disease. N Engl J Med 2016; 375: 2096-2098
  • 12 Coughlan MT, Sharma K. Challenging the dogma of mitochondrial reactive oxygen species overproduction in diabetic kidney disease. Kidney Int 2016; 90: 272-279
  • 13 Reidy K, Kang HM, Hostetter T. et al Molecular mechanism of diabetic kidney disease. J Clin Invest 2014; 124: 2333-2340
  • 14 Cherney DZ, Kanbay M, Lovshin JA. Renal physiology of glucose handling and therapeutic implications. Nephrol Dial Transplant 2020; 35: i1-i2
  • 15 Marton A, Kaneko T, Kovalik JP. et al Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. Nat Rev Nephrol 2021; 17: 65-77
  • 16 Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 2017; 60: 215-225
  • 17 McMurray JJV, Solomon SD, Inzucchi SE. et al Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381: 1995-2008
  • 18 Zinman B, Wanner C, Lachin JM. et al Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128
  • 19 Packer M, Anker SD, Butler J. et al Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383: 1413-1424
  • 20 Lee MMY, Brooksbank KJM, Wetherall K. et al Effect of Empagliflozin on Left Ventricular Volumes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF). Circulation 2020; DOI: 10.1161/CIRCULATIONAHA.120.052186. . Online ahead of print
  • 21 Brenner BM, Mark MD, Cooper E. et al Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. N Engl J Med 2001; 345: 861-869
  • 22 Perkovic V, Jardine MJ, Neal B. et al Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380: 2295-2306
  • 23 Bakris GL, Agarwal R, Anker SD. et al Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383: 2219-2229
  • 24 Heerspink HJL, Parving HH, Andress DL. et al Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 2019; 393: 1937-1947
  • 25 Armstrong PW, Pieske B, Anstrom KJ. et al Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2020; 382: 1883-1893
  • 26 McMurray JJV, Packer M. How should we sequence the treatments for heart faIlure and a reduced ejection fraction? A redefinition of evidencE-based Medicine. Circulation 2020; DOI: 10.1161/CIRCULATIONAHA.120.052926. . Online ahead of print
  • 27 Tuttle KR, Alicic RZ, Duru OK. et al Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children: An analysis of the CURE-CKD Registry. JAMA Netw Open 2019; 2: e1918169
  • 28 Wanner C, Inzucchi SE, Lachin JM. et al Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375: 323-334
  • 29 Heerspink HJL, Stefánsson BV, Correa-Rotter R. et al Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383: 1436-1446